AI-Driven Pathology and Blood-Based Biomarkers: A Golden Opportunity to Democratize Precision Oncology

Advancing global health equity requires a paradigm shift in precision oncology, which currently remains inaccessible to most patients worldwide because of the high cost and long turnaround time of sequencing-based biomarkers. Recent developments in artificial intelligence inference from routine histopathology slides and blood tests are now enabling rapid cost-effective prediction of survival of patients with cancer and treatment response in both developed and under-resourced regions globally.